Verapamil

As a classic calcium channel blocker with more than 40 years of clinical application, verapamil exerts multiple effects of lowering blood pressure, slowing atrioventricular conduction and dilating coronary arteries by inhibiting the entry of calcium ions into vascular smooth muscle and myocardial cells. Clinically, it is not only used for the routine treatment of hypertension and angina pectoris, but also a first-line option for the control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation/flutter. The applicable population covers adult hypertensive patients, people with chronic stable angina pectoris and specific arrhythmia patients, and some off-label indications can also be used for the preventive treatment of migraine.

The market size of antihypertensive drugs in China has exceeded 110 billion yuan. As the category of antihypertensive drugs with the highest proportion, calcium channel blockers account for nearly 30% of the market share. As a classic variety among them, verapamil has stable demand in primary medical institutions, with an annual market size of about 800 million yuan and an annual compound growth rate of about 2.3%. At present, the domestic preparation market is dominated by generic drugs. More than 30 enterprises have passed the consistency evaluation for their oral dosage forms, and 7 enterprises for their injectable dosage forms. The winning bid price in centralized procurement has dropped by up to 92% compared with the original research drug, and the accessibility has been significantly improved.

The original research enterprise of verapamil is Abbott Laboratories, and the original trade name is Isoptin. The core compound patent of the drug expired globally in 1981. The dosage forms of the original research drug approved in China include 40mg, 80mg and 120mg common tablets, 240mg sustained-release tablets and 5mg/2mL injection. All dosage forms have been included in the Catalogue of Listed Drugs in China as reference preparations. As of now, there are 22 verapamil API registration records on the CDE API registration platform, of which 16 are in status A (approved for use in listed preparations). There are more than 50 verapamil preparation approvals in China, covering all dosage forms of oral immediate-release dosage forms, sustained-release dosage forms and injections. (Data as of November 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for verapamil API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. Meanwhile, the products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the full-process R&D and production needs of pharmaceutical enterprises such as impurity research, quality standard establishment and consistency evaluation.